Trial Profile
A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors National OncoVenture
- 05 Jan 2022 Status changed from active, no longer recruiting to completed.
- 30 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 30 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.